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Abstract		
	
The	regulation	of	brain	monoamine	levels	is	paramount	for	cognitive	functions	and	the	enzymes	
monoamine	oxidases	(MAO	A	and	B)	play	a	central	role	in	these	processes.	The	aim	of	this	study	
was	 to	 evaluate	whether	 the	 pro-cognitive	 properties	 exerted	 by	 propargylamine	N-(furan-2-
ylmethyl)-N-methylprop-2-yn-1-amine	(F2MPA)	were	related	to	changes	in	monoamine	content	
via	 MAO	 inhibition.	 In	 vivo	 microdialysis	 and	 ex	 vivo	 amine	 metabolite	 measurement	
demonstrated	 region-specific	 alterations	 in	monoamine	metabolism	 that	differ	 from	both	 the	
classic	 MAO	 A	 or	 MAO	 B	 inhibitors	 clorgyline	 and	 L-deprenyl,	 respectively.	 Although	 all	 the	
inhibitors	(1	and	4	mg/kg)	increased	cortical	serotonin	tissue	content,	only	F2MPA	increased	the	
levels	of	cortical	noradrenaline.	In	the	striatum,	clorgyline	(1	mg/kg),	but	not	F2MPA	(1	mg/kg),	
reduced	extracellular	 levels	of	dopamine	metabolites	at	 rest	or	 stimulated	by	 the	 intrastriatal	
application	 of	 the	MAO	 substrate	 3-methoxytyramin.	 In	 vitro,	 F2MPA	 exhibited	 a	 low	 affinity	
toward	MAO	B	and	MAO	A.	Nonetheless,	it	modified	the	B	form	of	MAO,	forming	a	flavin	adduct	
structurally	similar	to	that	with	deprenyl.	F2MPA	was	rapidly	metabolized	in	the	presence	of	rat,	
but	not	human,	microsomes,	producing	a	hydroxylated	derivative.	 In	conclusion,	 the	effect	of	
F2MPA	on	cognition	may	arise	from	monoaminergic	changes	in	the	cortex,	but	the	role	of	MAO	
in	this	process	is	likely	to	be	negligible,	consistently	to	the	F2MPA	poor	affinity	for	MAO.	
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1. Introduction	
The	 monoamine	 neurotransmitters	 dopamine	 (DA),	 adrenaline,	 noradrenaline	 (NA)	 and	
serotonin	 (5-HT)	 are	 aromatic	 molecules	 released	 by	 neurons	 in	 the	 central	 nervous	 system	
(CNS)	to	regulate	cognitive	processes	1,	though	they	also	have	roles	in	peripheral	tissues	2.	These	
neuroactive	 amines	 are	 paramount	 in	 mood	 control,	 behavior,	 emotional	 life,	 memory	 and	
many	other	cognitive	processes	in	the	adult	brain.	Impairment	in	metabolism	and	regulation	of	
neurotransmitters	 may	 lead	 to	 serious	 diseases	 whose	 complexity	 reflects	 the	 multi-faceted	
functions	of	these	endogenous	compounds	3.	Among	these	pathological	conditions,	Alzheimer’s	
disease	(AD)	and	other	dementias	are	increasing	in	the	ageing	populations	and	their	economical	
and	social	impact	is	becoming	a	worrisome	burden	4.	Besides	aggregation	of	misfolded	proteins	
and	 general	 neuronal	 depletion,	 oxidative	 stress	 is	 being	 investigated	 as	 one	 of	 the	 factors	
contributing	 to	AD	development,	 although	antioxidant	 therapies	have	proved	unsuccessful	 so	
far	 5.	 In	 this	 context,	 the	 comprehension	of	 the	molecular	basis	of	AD	 is	 crucial	 to	define	 the	
underlying	 neurodegenerative	 mechanisms	 and	 to	 develop	 new	 drugs.	 In	 addition	 to	
acetylcholinesterase,	 human	 monoamine	 oxidases	 A	 and	 B	 (hMAO	 A	 and	 hMAO	 B)	 are	
considered	 as	 possible	 AD	 targets	 to	 preserve	 neurotransmitters.	 The	 inhibitors	 of	MAO	 also	
reduce	the	oxidative	stress	of	hydrogen	peroxide	produced	during	the	catalyzed	reaction	and,	
moreover,	 some	 of	 the	 propargyl	 compounds	 exert	 a	 neuroprotective	 effect	 by	 other	
mechanisms	 6-7.	 MAOs	 are	 mitochondrial	 membrane	 proteins	 that	 regulate	 the	 levels	 of	
monoamine	 neurotransmitters	 in	 both	 CNS	 and	 peripheral	 tissues	 by	 oxidizing	 the	 substrate	
amino	group	 through	 the	enzyme-bound	FAD	cofactor,	which	 is	 then	 reoxidized	by	molecular	
oxygen	with	the	release	of	hydrogen	peroxide	8.	
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(Please	insert		Figure	1	here)	
	
A	 number	 of	 MAO	 inhibitors	 (MAOIs)	 have	 been	 developed,	 but	 only	 a	 few	 of	 them	 are	
currently	 used	 in	 the	 clinical	 practice,	mainly	 to	 treat	 Parkinson’s	 disease	 and	 some	 types	 of	
depression	 9-10.	 Although	 encoded	 by	 different	 genes	 11,	 MAO	 A	 and	 MAO	 B	 feature	 partly	
overlapping	 substrate	 specificity	 as	 well	 as	 similar	 biochemical	 and	 structural	 properties.	
Therefore,	 selectively	 targeting	 one	 of	 the	 two	 isozymes	 or	 even	 identifying	 the	 individual	
involvement	of	each	in	a	particular	process	or	disease	is	a	difficult	task.	Historically,	MAO	A	and	
MAO	B	are	specifically	 inhibited	by	clorgyline	and	deprenyl,	respectively,	both	being	propargyl	
amines	which	 irreversibly	and	covalently	 inactivate	 the	enzymes.	 In	2014,	we	 reported	a	new	
inhibitor	 of	 this	 class,	 N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine	 (F2MPA,	 Figure	 1),	
which	showed	enhancement	of	basic	synaptic	transmission	in	the	hippocampus	of	rats	12.	In	that	
report,	F2MPA	had	a	striking	effect	on	the	rat	dentate	gyrus	electrophysiology,	similar	to	that	of	
the	 long-lasting	 potentiation	 effect	 of	 NE.	 It	 was	 suggested	 that	 it	 might	 be	 a	 promising	
candidate	for	new	therapies	to	improve	cognitive	conditions	in	AD	patients.	Both	the	theoretical	
calculations	and	its	in	vivo	efficacy	at	1	mg/kg	indicated	that	F2MPA	may	feature	a	good	profile	
as	a	CNS	drug.	We	speculated	 that,	although	 the	 initial	 tests	 showed	a	 low	affinity	of	F2MPA	
toward	MAOs,	 the	 in	vivo	effects	of	F2MPA	could	be	related	to	a	modification	of	monoamine	
function	through	the	inhibition	of	MAO	activities.	
In	the	present	study,	we	carried	out	a	multi-approach	study	to	investigate	MAO	inhibition	by	
F2MPA	 and	 to	 correlate	 it	 to	 the	 effects	 on	 monoamine	 levels	 in	 the	 brain.	 We	 performed	
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enzymatic	 assays	 and	 structural	 analyses	 that	 confirmed	 F2MPA	 as	 an	 irreversible	 MAO	 B-
specific	 inhibitor,	 but	 comparative	 ex	 vivo	 and	 microdialysis	 experiments	 suggested	 that	 the	
effects	of	F2MPA	in	vivo	are	likely	to	be	unrelated	to	its	MAO	inhibitory	properties.	
		
 
Results	and	Discussion	
 
Comparative	analysis	of	F2MPA	effect	on	monoamine	levels	in	rats	
Tissue	measurement	experiments	in	rats	were	carried	out	to	evaluate	and	compare	the	effects	
of	F2MPA	and	the	classical	MAOI	clorgyline	and	deprenyl	on	tissue	 levels	of	monoamines	and	
metabolites	 in	 the	 striatum,	 the	 cortex	 and	 the	 hippocampus.	 Based	 on	 the	 previous	 study	
reporting	a	strong	effect	of	F2MPA	at	1	mg/kg	12,	we	selected	the	doses	of	1	and	4	mg/g	for	all	
drugs	(Table	1).	Although	all	compounds	significantly	enhanced	5-HT	content	in	the	cortex,	the	
main	 result	 is	 that	 all	 compounds	 exhibited	 a	 distinct	 profile	 on	monoamine	 tissue	 content.	
Deprenyl	did	not	produce	any	other	 alteration	on	monoamine	 tissue	 contents	 at	 these	doses	
whatever	 the	 region.	Conversely,	 clorgyline	significantly	enhanced	striatal	DA	 levels	 (an	effect	
mainly	observed	at	the	dose	of	4	mg/kg)	while	decreasing	DOPAC	levels	and,	to	a	lower	extent,	
also	homovanillic	acid	HVA	whatever	the	dose	administered.	These	dopaminergic	effects	were	
not	observed	 in	the	cortex.	 In	the	hippocampus,	clorgyline	decreased	5-HIAA	tissue	 levels	and	
tended,	 though	 not	 significantly,	 to	 increase	 5-HT.	 Like	 deprenyl,	 clorgyline	 did	 not	 alter	 NE	
content	whatever	the	regions.		
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The	 data	 with	 clorgyline	 recall	 that	 MAO	 A	 is	 mainly	 involved	 in	 the	 regulation	 of	 the	
dopaminergic	system	in	the	striatum	13-18,	but,	elsewhere,	its	role	in	the	metabolism	of	DA	and	
of	 5-HT	 is	 region-dependent	 8,	 16.	 The	 lack	 of	 effect	 of	 clorgyline	 on	NE	 tissue	 content	 is	 not	
surprising	because	it	usually	requires	higher	non-selective	doses	or	chronic	treatment	to	have	a	
pronounced	effect.	Although	both	MAO	isoforms	are	present	in	all	brain	regions	19-21,	a	general,	
less	pronounced	effect	of	deprenyl	with	respect	 to	clorgyline	was	confirmed	8,	 16.	 It	 should	be	
noted	 that,	 apart	 from	 its	presence	 in	 serotonergic	neurons,	MAO	B	 is	present	mainly	 in	glial	
cells	 and	 astrocytes,	 whereas	 MAO	 A	 is	 predominantly	 expressed	 in	 all	 neurons	 with	 the	
exception	of	serotonergic	neurons	19-20.	
Although	 the	 tissue	 data	 confirmed	 that	 F2MPA	 is	 already	 efficacious	 at	 1	 mg/kg	 12,	 its	
neurochemical	 profile	 on	 monoamines	 did	 not	 correspond	 to	 the	 neuropharmacological	
signature	of	either	a	MAO	A	or	a	MAO	B	inhibitor.	Indeed,	at	variance	with	clorgyline,	it	did	not	
alter	the	dopaminergic	metabolism	in	the	striatum.	Rather,	F2MPA	slightly	decreased	striatal	DA	
only	at	the	dose	of	1	mg/kg	without	altering	DOPAC	content,	and	it	increased	HVA	at	the	dose	
of	 4	 mg/kg.	 Although	 we	 could	 not	 measure	 DA	 in	 the	 cortex	 in	 this	 experiment	 due	 to	
unexpected	 loss	 of	 sensitivity,	we	 found	 that	 F2MPA	 increased	NE	 content	 specifically	 in	 the	
cortex.	In	contrast	to	its	excitatory	effect	on	5-HT	content	in	the	cortex,	F2MPA	reduced	striatal	
5-HT	 content	 and	 its	 metabolite	 as	 well.	 In	 some	 cases,	 F2MPA	 altered	 the	 monoamine	 or	
metabolite	levels	less	at	the	higher	dose,	in	particular	as	regard	the	enhancement	of	5-HT	tissue	
levels	in	the	cortex.		
(Please	insert	Figure	2	here)	
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To	better	investigate	an	interaction	of	F2MPA	on	both	resting	and	stimulated	MAO	function,	we	
focused	 on	 the	 extracellular	 levels	 of	 HVA,	 one	 end	 product	 of	 MAO	 activity	 22.	 A	 new	
pharmacological	approach	was	carried	out	using	intracerebral	reverse	microdialysis.	Exogenous	
3-methoxytyramin	 (3-MT,	 derived	 endogenously	 from	 dopamine	 through	 COMT	 activity)	 was	
applied	 into	 the	 striatum	 of	 rats	 at	 increasing	 concentrations	 and	 extracellular	 levels	 of	 HVA	
were	monitored	along	the	experiment.	We	choose	3-MT	over	the	infusion	of	neurotransmitters	
themselves	to	monitor	the	activity	of	MAO	because	the	metabolic	link	between	MAO	and	HVA	
involves	two	enzymatic	steps,	like	5-HT	and	5-HIAA,	but	it	recruits	two	parallel	circuits	in	case	of	
DA	and	HVA	22,23.	Moreover,	while	3-MT	would	generate	few	off	targets	on	its	own	23,	biogenic	
amines	would	have	produced	a	number	of	other	effects	related	to	their	receptors,	transporters,	
and	 enzymes	 that	 would	 have	 profoundly	 alter	 local	 cell	 activities	 and	 impaired	 the	
interpretation	of	the	data	regarding	MAO	activity.	The	effect	of	clorgyline	and	F2MPA	on	basal	
and	 3-MT-stimulated	 extracellular	 levels	 of	 HVA	 in	 the	 striatum	 are	 reported	 in	 Figure	 2.	 As	
expected,	 3-MT	 application	 induced	 a	 concentration-dependent	 increase	 in	 HVA	 extracellular	
levels	 in	 the	 striatum	 reaching	 approximately	 150,	 240	 and	 740%	 of	 baseline	 values	 when	
applied	 at	 1,	 10	 and	100µM,	 respectively.	 The	application	of	 3-MT	did	not	 alter	DOPAC	or	 5-
HIAA	 extracellular	 levels	whatever	 the	 applied	 concentration	 (data	 not	 shown).	 The	 systemic	
injection	 of	 1	 mg/kg	 clorgyline	 significantly	 reduced	 the	 increase	 in	 HVA	 extracellular	 levels	
induced	by	the	application	of	3-MT.	Significant	effects	were	observed	for	all	concentrations	of	
applied	 3-MT	 (two-way	 ANOVA,	 F(1,17)	with	 p<0.05	 for	 each	 time	 point	 from	 the	 30-minute	
time-point	until	 the	end	of	 the	monitoring).	The	 reduction	of	 the	effect	of	3-MT	by	clorgyline	
was	more	important	at	the	lower	concentrations	of	3-MT	and	partial	(almost	50%	blockade)	at	
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the	 highest	 concentration.	 The	 trend	 toward	 a	 reduction	 of	 HVA	 levels	 with	 clorgyline	 was	
significant	 with	 respect	 to	 control	 group	 90	 min	 after	 its	 administration	 during	 45	 min.	 We	
performed	 a	 separate	 comparison	 between	 the	 control	 group	 and	 the	 group	 treated	 with	
clorgyline	 because	 this	 statistical	 profile	 was	 dependent	 on	 the	 context	 of	 the	 four	 groups.	
Clorgyline	 per	 se	 inhibited	 HVA	 extracellular	 levels,	 the	 values	 being	 significantly	 lower	
compared	to	the	control	groups	1	h	after	its	administration	till	the	end	of	the	monitoring.	It	 is	
noteworthy	 that	 clorgyline	 also	 significantly	 reduced	 DOPAC	 and	 5-HIAA	 extracellular	 levels	
(Student’s	 t-test;	 data	 not	 shown).	 Conversely,	 F2MPA	 did	 not	 modify	 the	 increase	 in	 HVA	
extracellular	levels	induced	by	the	application	of	3-MT	(two-way	ANOVA,	F(1,19)	with	p>0.05	for	
the	 12	 time	 points	 of	 the	 time	 course;	 Figure	 3,	 right	 panel).	 A	 separate	 statistical	 analysis	
between	 the	 control	 group	and	 the	F2MPA	group	also	 confirmed	 that	 F2MPA	did	not	modify	
basal	 extracellular	 levels	 of	 HVA	 (Figure	 2),	 DOPAC	 or	 5-HIAA	 (ns,	 Student’s	 t-test;	 data	 not	
shown).	
Intracerebral	microdialysis	is	a	much	more	sensitive	approach	for	the	study	of	MAO	A	function	
compared	to	tissue	measurement	as	exemplified	 in	this	study	with	clorgyline.	The	finding	that	
F2MPA	 altered	 neither	 basal	 nor	 3-MT-stimulated	 extracellular	 levels	 of	 HVA	 in	 contrast	 to	
clorgyline	 suggests	 that	 the	 effects	 reported	 previously	 in	 vivo	 12	 or	 in	 this	 study	 ex	 vivo	 are	
unrelated	 to	 MAO	 inhibition.	 Nonetheless,	 MAOIs	 administered	 acutely	 have	 complex	 and	
regional	 effects	 on	monoamine	 content	 13.	 Their	 monoaminergic	 effects	 can	 result	 from	 the	
blockade	 of	 MAO	 activity,	 which	 itself	 differ	 within	 the	 various	 brain	 regions	 and	
monoaminergic	systems	13,	22.	In	addition,	their	primary	effects	could	be	modulated	by	complex	
monoaminergic	 interactions	that	are	still	difficult	to	decipher	 in	some	cases	24,25.	For	 instance,	
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the	 enhancement	 of	 cortical	 5-HT	 by	 both	MAOI	 could	 dampen	 the	 enhancement	 of	 striatal	
and/or	 hippocampal	 5-HT	 via	 long	 loops	 involving	 the	 raphe	 nuclei26.	 The	 effects	 of	 MAO	
inhibitors	are	also	strictly	dependent	on	 the	reversible	or	 irreversible	nature	of	 their	mode	of	
binding	to	MAO	enzymes,	so	we	addressed	this	aspect	in	vitro	for	F2MPA.	
	
Characterization	of	hMAO	A	and	hMAO	B	inhibition	by	F2MPA	
To	 probe	 hMAO	 inhibition	 by	 F2MPA,	 the	 fluorometric	 horseradish	 peroxidase-coupled	 assay	
described	in	the	method	was	used	to	determine	IC50	values	for	initial	binding,	which	were	214	±	
17	μM	 for	hMAO	A	and	111	±	4	μM	 for	hMAO	B.	To	 test	 for	 irreversible	 inhibition	after	pre-
incubation,	the	IC50	was	also	determined	after	30	min	preincubation	at	30°C.	For	hMAO	A,	the	
IC50	was	232	±	15	μM,	not	significantly	different	from	the	value	measured	without	 incubation,	
suggesting	that	hMAO	A	is	not	irreversibly	inactivated	by	F2MPA.	In	contrast,	the	IC50	for	MAO	B	
after	 30	 min	 preincubation	 was	 8.9	 ±	 1.2	 μM	 suggesting	 that	 hMAO	 B	 was	 irreversibly	
inactivated	after	pre-incubation	with	F2MPA	in	a	time-	and	concentration-dependent	manner.	
These	results	prompted	further	experiments	to	determine	the	 inactivation	rate	parameters	by	
the	Kitz	and	Wilson	method	27-28	as	shown	in	Table	2.	hMAO	B	inactivation	by	F2MPA	gave	a	KI	
value	 of	 135	 ±	 23	 μM	 and	 kinact	 of	 0.61	 ±	 0.09	 min-1.	 For	 comparison,	 the	 typical	 MAO	 B	
inactivator,	deprenyl,	gave	a	KI	of	0.18	±	0.01	μM	and	kinact	of	1.06	±	0.03	min-1.	For	hMAO	B,	the	
specificity	constant	(kinact/KI)		shows	that	FMPA	is	three	orders	of	magnitude	less	effective	than	
deprenyl.	 The	 detailed	 investigation	 also	 revealed	 that,	 with	 high	 concentrations	 and	 longer	
times,	MAO	A	was	also	inactivated	although	the	rate	constant	was	seven	times	slower	(kinact	=	
0.087	min-1)	 than	 for	MAO	B.	 That	 FMPA	 is	 four	 orders	 of	magnitude	 less	 effective	 than	 the	
11	
	
MAO	A-selective	 inactivator,	 clorgyline,	 is	 clear	 from	 the	 specificity	 constant	which	 is	 5	min-1	
μM-1	for	clorgyline	but	only	0.0005	min-1	μM-1	for	FMPA	on	MAO	A	(Table	2).			
	
As	the	formation	of	the	covalent	adduct	occurred	over	a	time	range	of	minutes,	we	were	able	to	
measure	 by	 the	 spectrophotometric	 assay,	 the	 reversible	 inhibition	 of	 hMAO	 B	 by	 F2MPA.	
F2MPA	competitively	inhibits	hMAO	B	with	a	Ki	of	317	±	86	μM.	This	and	the	high	IC50	values	
without	preincubation	indicate	that	the	affinity	for	reversible	binding	to	either	hMAO	A	or	B	is	
very	 low,	 suggesting	 that	 inactivation	 of	 hMAO	 B	 in	 vivo	 may	 be	 difficult	 to	 achieve	 (while	
almost	impossible	for	hMAO	A	with	its	very	slow	kinact).		
	
(Please	insert	Figure	3	here	-	structure)		
	
The	structure	of	the	F2MPA-MAO	B	adduct	
Inspection	of	the	UV-visible	spectrum	of	F2MPA-inactivated	MAO	B	showed	the	same	modified	
flavin	peak	(data	not	shown)	encountered	with	other	propargyl	inhibitors	such	as	deprenyl	29-30,	
which	suggested	that	F2MPA	may	form	a	similar	covalent	adduct	with	the	hMAO	B	cofactor.	The	
crystal	structure	of	hMAO	B	in	complex	with	F2MPA	was	solved	at	2.4	Å.	The	electron	density	
map	of	 the	 inhibitor	 is	continuous	with	 that	of	 the	FAD	cofactor,	 indicating	 that	 the	 flavin	N5	
atom	reacted	with	the	propargyl	unit	of	 the	compound	forming	a	covalent	adduct	 (Figure	3A)	
which	 resembles	 those	 found	 for	 all	 the	 other	 inhibitors	 of	 this	 class	 30.	 Although	 F2MPA	 is	
identically	bound	in	either	of	the	two	protein	molecules	that	occupy	the	asymmetric	unit	(rmsd	
=	 0.27	 Å),	 the	 adduct	 is	 slightly	 better	 defined	 in	 subunit	 B	 and	 we	 will	 refer	 to	 it	 for	 the	
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following	discussion.	The	 furan	 ring	of	F2MPA	 lies	 in	 the	 rear	of	 the	substrate	cavity	with	 the	
gating	 Ile199	 side	 chain	adopting	 the	open	conformation.	 Some	degree	of	 ambiguity	exists	 in	
the	exact	position	of	the	furan	oxygen	atom	because	the	ring	could	rotate	180°	along	the	axis	of	
the	propargyl	side	chain.	On	the	basis	of	the	electron	density	 it	 is	not	possible	to	discriminate	
between	the	 two	possibilities	and	 in	either	case	 the	oxygen	would	not	be	at	H-bond	distance	
with	 any	 residue	 to	 predict	 one	 conformation	 as	 the	 most	 favorable.	 In	 the	 final	 refined	
structure,	the	inhibitor	was	modelled	with	the	furan	oxygen	pointing	towards	the	bottom	of	the	
cavity,	 as	 this	 portion	 of	 the	 active	 site	 is	 occupied	 by	 water	 molecules	 and,	 therefore,	 is	
presumably	 less	hydrophobic.	However,	 it	 cannot	be	 ruled	out	 that	 the	 furan	 ring	may	 freely	
rotate	without	adopting	a	fixed	unique	conformation.	The	F2MPA	molecule	is	in	van	der	Waals	
contact	with	 the	enzyme	active	 site	 residues	 (Figure	3B),	whose	 conformation	 is	 the	 same	as	
that	 found	 in	 other	 hMAO	 B	 structures.	 The	 position	 of	 the	 three	 solvent	 molecules	 at	 the	
bottom	of	the	substrate	cavity	in	front	of	the	flavin	is	also	conserved	as	is	the	water	molecule	
that	mediates	the	H-bond	interaction	between	Lys296	and	the	flavin	N5	atom.	Superposition	of	
the	 hMAO	 B-pargyline	 structure	 (PDB	 code	 1GOS)	 onto	 the	 enzyme	 in	 complex	 with	 F2MPA	
revealed	 a	 high	 similarity	 (Figure	 3B),	 in	 particular	 in	 the	 position	of	 the	 acetylenic	 atoms.	 In	
addition,	 the	 N-CH3	 group	 adopts	 a	 similar	 conformation	 with	 the	 methyl	 group	 pointing	
towards	Tyr435,	whereas	the	furan	ring	is	oriented	in	the	same	plane	as	the	aromatic	moiety	of	
pargyline.	The	F2MPA	adduct	is	very	well	conserved	also	with	respect	to	the	hMAO	B-deprenyl	
structure	(PDB	code	2BYB),	with	the	main	difference	existing	in	the	position	of	the	aromatic	ring	
of	deprenyl	that,	because	its	acetylenic	chain	is	longer,	lies	further	to	the	rear	of	the	active	site	
cavity	(Figure	3C).	The	hMAO	B	crystal	structure	showed	that	F2MPA	forms	a	covalent	adduct	
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highly	similar	to	that	found	by	other	propargyl	 inhibitors	 including	deprenyl	(Figure	3C),	which	
implies	that,	once	bound	to	the	active	site,	F2MPA	inactivates	the	enzyme	as	stably	as	deprenyl.	
	
Metabolic	stability	of	F2MPA	
The	 discrepancy	 of	 the	 effects	 in	 vivo	 from	 that	 expected	 for	 a	 MAO	 B-specific	 inactivating	
inhibitor	 led	 us	 to	 investigate	whether	 in	 vivo	metabolism	of	 F2MPA	 could	 be	 occurring.	 The	
metabolic	stability	of	F2MPA	was	assessed	upon	incubation	with	human	or	rat	liver	microsomal	
preparations.	 The	plot	of	 the	natural	 logarithm	of	 the	non-metabolized	 compound	 (%)	 versus	
time	was	linear	(Figure	4),	indicating	that	the	substrate	depletion	followed	a	monoexponential	
relationship.	With	human	liver	microsomes,	the	calculated	rate	constant	(k)	for	the	decay	was	
0.002156	min-1,	which	corresponds	to	a	half-life	time	of	t½	321	min,	and	the	resulting	Clint	was	
5.39	 μL/min	 per	 mg	 of	 protein.	 In	 contrast,	 rat	 microsomes	 were	 able	 to	 metabolize	 the	
compound	at	very	high	rate,	with	a	t½	of	only	10.0	min	and	an	intrinsic	clearance	of	182	μL/min	
per	mg	protein.	
	
The	 MS	 analysis	 of	 the	 incubation	 mixture	 of	 rat	 microsomes	 revealed	 the	 presence	 of	 a	
metabolite	 at	 [M+16]+	 (m/z)	 identified	 as	 a	 derivative	hydroxylated,	 probably	 on	 the	position	
6		on	the	furan	ring	according	with	MetaSite	 in	silico	analysis	31.	Conversely,	the	 incubation	of	
F2MPA	 (up	 to	50	µM)	with	human	microsomes	did	not	 reveal	 any	metabolite(s)	produced	by	
cytochromes	 P450	 (CYP).	 These	 results	 clearly	 indicate	 that	 F2MPA	 is	 not	 a	 substrate	 of	 any	
human	liver	CYPs	(or	a	very	poor	one),	whereas	it	features	a	very	low	metabolic	stability	in	rats.	
These	divergent	behaviors	between	human	and	rat	have	to	be	considered	for	the	interpretation	
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of	 the	ex	 vivo/in	 vivo	 described	 above.	 In	 the	 rat	 studies,	 F2MPA	 is	 rapidly	metabolised	 and,	
although	 the	 hydroxylated	 derivative	 of	 F2MPA	 may	 still	 inhibit	 MAO	 B,	 the	 fact	 that	 the	
cognitive-enhancing	 properties	 of	 the	 inhibitor	 appear	 to	 be	MAO-independent	 suggests	 that	
this	metabolite	might	act	also	on	other	targets.	
 
Conclusions	
A	combination	of	neurochemical,	metabolic	and	biochemical	studies	were	performed	to	dissect	
the	MAO	inhibitory	properties	of	F2MPA,	a	propargyl-containing	compound	that	was	previously	
highlighted	 for	 its	 cognitive-enhancing	 effects	 (Figure	 1;	 Di	 Giovanni	 et	 al.,	 2014).	 The	 main	
result	 of	 this	 study	 is	 that	 tissue	 measurement	 experiments	 showed	 that	 F2MPA	 produces	
changes	in	rat	brain	monoamine	levels,	such	as	a	combined	increase	in	5-HT	and	NE	levels	in	the	
cortex,	 which	 are	 distinct	 from	 those	 induced	 by	 the	 typical	 MAO	 inhibitors	 clorgyline	 and	
deprenyl.	 The	 dissimilarity	 is	 consistent	 with	 the	 weak	 inhibition	 properties	 of	 F2MPA	 with	
respect	to	both	isozymes	(IC50	values	are	214	μM	and	111	μM	for	human	MAO	A	and	MAO	B,	
respectively).	The	crystal	structure	of	human	MAO	B	in	complex	with	F2MPA	revealed	that	the	
inhibitor	 does	 form	 a	 covalent	 adduct	 with	 the	 enzyme	 flavin	 cofactor	 similarly	 to	 other	
acetylenic	 compounds	 such	 as	 deprenyl	 and	 rasagiline.	 However,	 irreversible	 inactivation	 of	
MAO	B	gave	a	KI	value	of	193	μM	and	kinact	of	0.252	min-1,	indicating	that	F2MPA	is	much	weaker	
than	deprenyl	but	similarly	fast	in	forming	the	covalent	adduct	with	FAD	observed	in	the	crystal	
structure.	Metabolic	stability	investigations	showed	some	discrepancies	between	human	and	rat	
systems,	with	the	latter	featuring	a	CYP-dependent	formation	of	a	F2MPA	metabolite	that	is	not	
observed	in	humans.	As	binding	affinity	values	were	measured	with	rat	MAOs	which	are	similar	
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to	 those	 found	 for	 the	 human	 enzymes	 (Table	 2),	 it	 can	 be	 concluded	 that	 the	 pro-cognitive	
profile	of	F2MPA	described	earlier	12	could	be	related	to	a	still	unknown	action	on	monoamine	
systems,	 which	 is	 independent	 from	 its	 very	 poor	 MAO	 inhibition	 properties.	 A	 full	
pharmacological	 description	 of	 its	 binding	 profile	 on	 various	 receptors,	 enzymes	 and	
transporters	is	still	not	available,	impairing	any	further	comments	on	its	mechanism	of	action.		
 
Methods	
Chemicals	and	reagents		
Deprenyl	hydrochloride,	 clorgyline	hydrochloride,	3-methoxytyramine	 (3-MT)	hydrochloride	as	
well	 as	 all	 compounds	 for	 neurochemistry	 (dopamine	 hydrochloride,	 noradrenaline	
hydrochloride,	 serotonin	hydrochloride,	 3,4-dihydroxyphenylacetic	 acid	 (DOPAC),	 homovanillic	
acid	 (HVA),	 or	 5-hydroxyindolacetic	 acid,	 5-HIAA)	 and	 other	 reagents	 were	 purchased	 from	
Sigma-Aldrich.	F2MPA	was	synthesized	as	before	12.	Compounds	were	dissolved	in	sterile	NaCl	
0.9%	for	their	systemic	injection	in	animals.			
	
Animals		
Experiments	were	performed	on	79	male	Sprague-Dawley	rats	(Charles	River,	L’Arbresle	Cedex,	
France)	weighing	250-300	g	on	arrival,	housed	under	a	12:12	h	 light:dark	cycle	with	 food	and	
water	ad	libitum.	All	experiments	involving	animals	are	reported	in	accordance	with	the	ARRIVE	
guidelines	(see	legends	to	figures).	Protocols	were	approved	by	the	Ethical	Committee	of	Centre	
National	 de	 la	 Recherche	 Scientifique,	 Région	 Aquitaine-Limousin	 (Agreements	 n°50120166-A	
and	50120126-A).	All	experiments	conformed	to	European	Economic	Community	(86-6091	EEC)	
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and	 French	 National	 Committee	 (décret	 87/848,	 Ministère	 de	 l’Agriculture	 et	 de	 la	 Forêt)	
guidelines	 for	 the	 care	 and	 use	 of	 laboratory	 animals.	 All	 procedures	 were	 as	 humane	 as	
possible	and	efforts	were	made	to	reduce	the	number	of	animals	used.	
	
	
	
Microdialysis	
Rats	were	 anaesthetized	with	 isoflurane	 (3%)	 in	 a	 plastic	 chamber	 as	 previously	 described	 32.	
Animals	were	 then	 fixed	 on	 a	 stereotaxic	 apparatus	with	 a	 nose	mask	 adapted	 to	 it	 to	 allow	
continuous	 delivery	 of	 the	 anesthetic	 gas	 during	 probe	 implantation	 and	 microdialysis	
experiment	(isoflurane,	1.5%).	A	feedback-controlled	heating	pad	was	employed	to	keep	body	
temperature	at	37	°C.	The	tip	of	the	microdialysis	probe	(4	mm	length,	CMA/11,	240	µm	outer	
diameter;	Phymep,	France)	was	implanted	in	the	striatum	as	follow:	AP	=	9.7;	L	=	3;	V	=	2.4	with	
respect	 to	 the	 interaural	 point	 33.	 Perfusion	 of	 the	 microdialysis	 probe	 with	 the	 artificial	
cerebrospinal	fluid	(aCSF)	(154.1	mM	Cl-,	147	mM	Na+,	2.7	mM	K+,	1	mM	Mg2+	and	1.2	mM	Ca2+	
adjusted	to	pH	7.4	with	2	mM	sodium	phosphate	buffer)	was	performed	at	a	constant	flow	rate	
(2	 µl/min)	 with	 a	 microperfusion	 pump	 (CMA	 100,	 Phymep,	 France).	 Two	 hours	 after	
implantation	(a	timeframe	corresponding	to	steady-state	34,	dialysates	were	collected	every	15	
min	 and	 stored	 on	 ice.	 At	 the	 end	 of	 the	 experiment,	 anesthetized	 rats	 were	 sacrificed	 for	
histological	verification	of	the	correct	placement	of	the	microdialysis	probe.	
	
Chromatographic	analyses		
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Tissue	concentration	of	monoamines	and	their	metabolites	in	the	striatum,	the	cortex	and	the	
hippocampus	 was	 measured	 by	 reverse-phase	 high	 performance	 liquid	 chromatography	
coupled	with	electrochemical	detection	(HPLC-ECD).	Tissues	were	homogenized	in	100	µl	of	0.1	
N	HClO4	and	then	centrifuged	(13,000	rpm,	30	min,	4	°C).	Aliquots	(10	µl)	of	the	supernatants	
were	 injected	 into	 the	 HPLC	 column	 (Chromasyl	 C8,	 150	 X	 4.6	 mm,	 5	 µm)	 protected	 by	 a	
Brownlee-Newgard	precolumn	(RP-8,	15	x	3.2	mm,	7	µm).	The	mobile	phase	(60	mM	NaH2PO4	,	
0.1	mM	 disodium	 EDTA,	 2	mM	 octane	 sulfonic	 acid	 with	 7%	methanol,	 with	 the	 addition	 of	
orthophosphoric	acid	 to	adjust	pH	at	3.9)	was	delivered	at	1.2	ml/min	 flow	rate.	Detection	of	
compounds	was	performed	with	a	coulometric	detector	(CoulochemII,	ESA)	coupled	to	a	dual-
electrode	analytic	cell	(model	5011).	Electrodes	were	set	at	+350	and	-270	mV	potential.	Results	
were	 expressed	 as	 picograms	 per	 milligram	 of	 tissue,	 with	 each	 value	 corresponding	 to	 the	
mean	±	the	standard	error	of	the	mean	(s.e.m.).	
	
Each	 dialysate	 sample	 (30	 µl)	 was	 analyzed	 by	 HPLC-ECD	 as	 described	 previously	 32,	 34.	 The	
mobile	phase	(70	mM	NaH2PO4,	0.1	mM	EDTA,	0.1	mM	octylsulfonic	acid	with	10%	methanol,	
with	the	addition	of	orthophosphoric	acid	to	adjust	pH	at	4.5)	was	delivered	by	an	Equisyl-BDS	
column	(C18;	4.6	X	150	mm;	particle	size	5	µm;	CIL-Cluzeau,	Sainte-Foy	La	Grande,	France)	at	1	
ml/min	 flow	rate	 (Beckman	pump	116).	Detection	of	DOPAC,	HVA	and	5-HIAA	was	performed	
with	an	amperometric	cell	Ag/AgCl	(VT-03)	coupled	to	a	detector	(Decade	II	Antec,	AlphaMos,	
Toulouse,	France).	Electrodes	were	set	at	+600	mV	potential	and	output	signals	were	recorded	
(Beckman,	system	GOLD).		
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Pharmacological	treatments	
For	post-mortem	studies,	rats	were	habituated	for	one	week	to	the	room	in	which	they	received	
the	 MAOI	 clorgyline,	 deprenyl	 or	 F2MPA.	 On	 the	 day	 of	 the	 experiment,	 rats	 were	 given	
intraperitoneally	1	or	4	mg/kg	of	MAOI	or	the	vehicle	(sterile	NaCl	0.9%)	randomly	between	10	
and	12	am.	Rats	were	sacrificed	3	h	after	the	injection.	The	brains	were	quickly	removed,	frozen	
in	cold	 isopentane	(-35	°C),	and	kept	at	 -80	°C	pending	the	dissection	of	structures	of	 interest	
(striatum,	 frontal	 cortex,	 hippocampus)	 and	 the	 biochemical	 analysis.	 In	 dialysis	 experiments,	
the	pharmacological	treatments	started	after	the	stabilization	of	HVA	extracellular	levels	in	the	
dialysates.	3-MT,	dissolved	 in	aCSF,	was	applied	 through	 the	microdialysis	probe	at	 increasing	
concentrations	 (1,	 10	 and	 100	 µM)	 for	 1	 h	 each	 using	 a	 three-way	 liquid	 switch	 system	
(CMA111,	 Phymep).	 Control	 groups	 underwent	 the	 same	 procedures	 but	 syringes	 contained	
only	aCSF.	MAOIs	(clorgyline	or	F2MPA)	were	administered	intraperitoneally	at	1	mg/kg	15	min	
before	 the	 first	 application	 of	 3-MT	 or	 aCSF.	 Vehicle	 groups	 received	 the	 inhibitor	 solvent	
(sterile	NaCl	0.9%	in	all	cases).	
	
Inhibition	studies	
Both	 hMAO	 A	 and	 hMAO	 B	 were	 produced	 as	 recombinant	 enzymes	 using	 yeast	 expression	
systems	and	purified	as	previously	described	29-30.	Spectrophotometric	and	fluorimetric	methods	
were	used	for	enzymatic	assays	on	both	hMAO	A	and	hMAO	B	to	characterize	F2MPA	inhibition	
properties.	First,	using	the	coupled	fluorescence	assay	and	membrane-bound	human	MAO	A	or	
B,	IC50	values	were	determined	from	initial	rates	(i.e.	without	pre-incubation)	in	the	presence	of	
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tyramine	 (0.8	mM	 for	MAO	A	 and	 0.32	mM	 for	MAO	B)	 corresponding	 to	 about	 2xKm,	 using	
Graphpad	PRISM	4	to	fit	the	data	to	a	three-parameter	curve:	
Y=Bottom	+	(Top-Bottom)/(1+10^(X-LogIC50)	
Where	 the	 full	 curve	was	 not	 defined,	 the	 bottom	was	 set	 to	 zero.	 The	 results	 provided	 the	
proper	 experimental	 conditions	 for	 pre-incubation	 assays	 to	 test	 F2MPA	 for	 irreversible	
inhibition	 and	 to	 determine	 the	 inactivation	 rate	 (kinact)	 and	 inhibition	 constant	 (KI)	 27-28.	 As	
described	 previously	 30,	 enzyme	 and	 inhibitor	 were	 incubated	 at	 30	 °C	 in	 50	mM	 potassium	
phosphate	pH	7.4	for	various	times	before	two-fold	dilution	by	adding	1	mM	tyramine	and	the	
reaction	mixture	containing	horseradish	peroxidase	(HRP,	1	unit/ml	final)	and	Ampliflu	Red	(20	
μM	 final)	 to	 measure	 the	 remaining	 enzyme	 activity	 with	 respect	 to	 the	 control	 (i.e.	 no	
inhibitor).	 The	 inactivation	 of	MAO	A	 by	 clorgyline	was	 too	 fast	 and	 too	 high	 affinity	 for	 this	
method,	so	MAO	A	was	preincubated	in	50	μL	in	a	quartz	cuvette	before	addition	of	450	μL	of	
50	mM	potassium	phosphate	pH	7.5	at	30°C	containing	300	μM	kynuramine	(10x	KM)	to	dilute	
the	clorgyline	and	measure	the	remaining	active	enzyme.	Rates	 (as	relative	fluorescence	units	
per	 second	 or	 as	 absorbance	 change	 per	minute)	 were	 normalized	 to	 the	 initial	 activity	 and	
plotted	as	the	natural	log	(ln)	of	the	fractional	remaining	activity	against	time.	Rates	(as	relative	
fluorescence	units	per	second,	rfu/s)	were	normalized	to	the	control	and	plotted	as	the	 log	of	
the	 fractional	 remaining	 activity	 against	 time.	 The	 rates	 (kobs)	 plotted	 against	 F2MPA	
concentration	 gave	 a	 rectangular	 hyperbola	 that	 was	 fitted	 by	 non-linear	 analysis	 using	 the	
equation:	
(Y	=	kinact*X/(KI	+	X))	
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For	rat	tissue	experiments,	inactivation	parameters	(kinact	and	KI)	were	determined	as	described	
previously	28,	30.	Rat	liver	homogenate	was	prepared	from	frozen	rat	liver	at	1g	in	5	mL	of	50	mM	
potassium	phosphate,	pH	7.5,	containing	0.2%	Triton	X-100.	Assays	contained	the	equivalent	of	
0.5	mg/ml	of	wet	tissue.	
In	 addition,	 the	 reversible	 inhibition	 of	 purified	 hMAO	 B	 by	 F2MPA	 was	 assessed	 in	 the	
absorbance	assay	using	the	substrates	kynuramine	(hMAO	A)	and	benzylamine	(hMAO	B)	at	pH	
7.5	as	previously	published	35.	
	
X-ray	crystallography	
Crystals	of	hMAO	B	were	grown	following	published	procedures	30	using	enzyme	incubated	with	
1	mM	F2MPA	 for	1	h	 (15-fold	excess	with	 respect	 to	protein	 concentration).	X-ray	diffraction	
data	 were	 collected	 at	 the	 X06SA	 beamline	 of	 SLS	 synchrotron	 (Villigen,	 Switzerland),	 which	
were	processed	by	MOSFLM	36	and	CCP4	programs	37.	Model	building	by	Coot	38	and	refinement	
by	Refmac5	39	were	carried	out	using	standard	protocols	30.	Statistics	are	reported	in	Table	3	and	
figures	were	produced	using	CCP4mg	40.	
	
Analysis	of	in	vitro	metabolism	of	F2MPA	in	rat	and	human	liver	microsomes	
F2MPA,	 dissolved	 in	 water,	 was	 incubated	 separately	 at	 10	 μM	 concentration	 in	 100	 mM	
phosphate	 buffer	 (pH	 7.4)	 with	 0.48	 mg/mL	 human	 or	 rat	 hepatic	 microsomal	 protein	 as	
previously	 reported	 41.	 The	 enzymatic	 reactions	 were	 initiated	 by	 addition	 of	 a	 NADPH	
regenerating	 system	 consisting	 of	 2	 mM	 ß-nicotinamide	 adenine	 dinucleotide	 phosphate	
(NADPH),	 10	 mM	 glucose-6-phosphate	 (G6P),	 0.4	 U/ml	 glucose-6-phosphate	 dehydrogenase	
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(G6PDH).	Reactions	were	terminated	at	regular	time	intervals	(overall	range	0-60	min)	by	adding	
a	 double	 volume	 of	 acetonitrile.	 All	 incubations	 were	 performed	 in	 triplicate.	 Samples	 were	
analyzed	 by	 mass	 spectrometry	 using	 an	 Agilent	 6540	 UHD	 Accurate-Mass	 Q-TOF	 LC/MS	
spectrometer	 operated	 in	 positive	 electrospray	mode.	 The	 experimental	 data	 obtained	 were	
analyzed	using	Mass-MetaSite,	a	computer	assisted	method	for	the	interpretation	of	LC–MSMS	
data	 that	 combines	 prediction	 of	 the	 Site	 of	 Metabolism	 (SoM)	 of	 the	 compound	 with	 the	
processing	 of	 MS	 spectra	 and	 rationalization	 based	 on	 fragment	 analysis	 42.	 The	 intrinsic	
clearance	(Clint)	was	calculated	by	the	equation:	
Clint	=	k(min-1)x	[V]/[P]	
where	k	is	the	rate	constant	for	the	depletion	of	substrate,	V	is	the	volume	of	incubation	in	μL	
and	P	is	the	amount	of	microsomal	proteins	in	the	incubation	medium	in	mg	43.		
Statistics	
The	effect	of	MAOIs	on	tissue	levels	of	monoamines	and	metabolites	was	analysed	by	a	one-way	
ANOVA	 using	 the	 dose	 (0,	 1	 or	 4mg/kg)	 as	 the	 main	 factor	 for	 each	 compound.	 In	 case	 of	
significance	 (p<0.05),	 it	 was	 followed	 by	 the	 protected	 least	 significant	 difference	 test	 (PLSD	
test)	to	allow	for	multiple	comparisons	between	groups.	The	effect	of	clorgyline	or	F2MPA	on	
basal	 and	 stimulated	 extracellular	 levels	 of	HVA	was	 analysed	by	 a	 two-way	ANOVA	 for	 each	
time	point	of	the	time	course	using	the	factors	MAOI	X	3-MT.	In	case	of	significance,	indicating	
that	the	effect	of	the	treatment	3-MT	is	modified	by	the	MAOI,	this	first	analysis	was	followed	
by	a	one-way	ANOVA	with	group	as	the	main	factor	in	order	to	perform	the	post	hoc	PLSD	test	
for	multiple	comparisons	between	groups.	We	also	performed	separate	analysis	using	repeated	
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measures	 to	 determine	 the	 own	 effect	 of	 the	 two	MAOIs	 on	 basal	 extracellular	 levels.	 In	 all	
cases,	p<0.05	was	the	criterion	for	statistical	significance.		
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Figure captions 
 
Figure 1. Structure of N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA), L-deprenyl and 
clorgyline. 
 
Figure 2. Time course of the effect of clorgyline (left panel) or F2MPA (right panel) on basal and 3-MT-
stimulated extracellular levels of HVA in the striatum. The MAOIs or their vehicle (sterile saline) were 
administered at 1 mg/kg intraperitoneally at the time corresponding to the arrow. 3-MT, dissolved in 
aCSF, was applied at 1, 10 and 100 µM for one hour at each concentration as indicated by the horizontal 
bars (white, 1 µM; grey 10 µM; black, 100 µM). Controls rats received aCSF only. Basal levels of HVA 
did not differ between groups before the administration of drugs and reached 3 ± 0.8 ng/30µl (n=20, 5 
animals per group in the clorgyline experiment) or 2.6 ± 0.7 ng/30µl (n=19, 4 to 5 animals per group in 
the F2MPA experiment). Clorgyline significantly reduced the increase in HVA extracellular levels 
induced by 3-MT; *p<0.05 versus aCSF/saline group; °p<0.05 versus 3MT/clorgyline group, PLSD test 
after significant two-way ANOVA for each time point of the time course of effect. 
 
Figure 3. Crystal structure of hMAO B in complex with F2MPA. (A) Zoomed-view ribbon representation 
(white) of hMAO B active site showing the covalent adduct formed by F2MPA (lawn green) with the 
enzyme flavin cofactor (yellow). Nitrogen, oxygen and phosphor atoms are blue, red and magenta, 
respectively. The unbiased 2Fo-Fc electron density map for the F2MPA-flavin adduct contoured at 1.2 σ is 
colored in blue. It is important to note that some ambiguity exists in the position of the furan ring oxygen 
(see text) (B) hMAO B active site residues (carbon atoms in white) lining the enzyme cavity occupied by 
F2MPA. Color code is as in Figure 2A and water molecules are represented as red spheres. Hydrogen 
bonds are drawn as dashed lines. The inhibitor-flavin adduct is superposed to that formed by pargyline 
(PDB code 1GOS) represented with carbon atoms in brown. (C) Superposition of the MAO B-deprenyl 
adduct (PDB code 2BYB) onto that formed by F2MPA. Color code is as in Figure 2B. 
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Figure 4. CYP-dependent metabolic depletion of 10 µM F2MPA in human (■) and rat (●) liver 
microsomal preparations. Results are presented graphically in ln of percentage of compound recovery 
(100% at time 0 min) as a function of incubation time. Data are presented as mean ± s.e.m, of three 
different experiments. 
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Table 1. Effect of the systemic injection of MAOIs on the tissue content of DA, NE, 5-HT and 
metabolites in the striatum, the cortex and the hippocampus of rats. 
 DA DOPAC HVA NE 5-HT 5-HIAA 
       
STRIATUM       
        vehicle 2890 ± 341 813 ± 110 709 ± 90 232 ± 42 201 ± 32 346 ± 76 
        Clor. 1 3163 ± 610 434 ± 84* 535 ± 100 206 ± 33 205 ± 47 429 ± 104 
        Clor. 4 7273 ± 1702* 386 ± 92* 438 ± 66 148 ± 14 305 ± 75 267 ± 51 
ANOVA F2,18= 4.2 # F2,18= 2.7 # F2,18= 1.1 F2,18= 0.5 F2,18= 0.6 F2,18= 0.9 
        Depr. 1 4160 ± 501 955 ± 85 772 ± 77 191 ± 33 124 ± 24 329 ± 63 
        Depr. 4 2895 ± 605 697 ± 102 678 ± 92 167 ± 25 169 ± 25 406 ± 55 
ANOVA F2,18= 1 F2,18= 0.6 F2,18= 0.7 F2,18= 0.7 F2,18= 1.8 F2,18= 0.4 
        vehicle 3457 ± 163 822 ± 8 666 ± 35 235 ± 11 355 ± 4 243 ± 10 
        F2MPA 1 2669 ± 143* 829 ± 15 664 ± 39 239 ± 10 162 ± 14* 172 ± 11* 
        F2MPA 4 3651 ± 84 859 ± 14 846 ± 17 258 ± 16 241 ± 18* 252 ± 10 
ANOVA F2,15= 15 # F2,15= 2.2 F2,15= 9.9 # F2,15= 0.9 F2,15= 52 # F2,15= 19 # 
       
CORTEX       
        vehicle 10 ± 1 50 ± 7 nd 359 ± 94 362 ± 27 278 ± 47 
        Clor. 1 11 ± 3 47 ± 10  170 ± 29 567 ± 14 202 ± 29 
        Clor. 4 14 ± 4 43 ± 5  228 ± 40 819 ± 13* 184 ± 27 
ANOVA F2,18= 0.4 F2,18= 0.2 nd F2,18= 2.3 F2,18= 4 # F2,18= 2 
        Depr. 1 13 ± 2 58 ± 9  195 ± 44 364 ± 21 464 ± 178 
        Depr. 4 48 ± 30 74 ± 16  257 ± 28 495 ± 41* 384 ± 89 
ANOVA F2,18= 3.1 F2,18= 1.2  F2,18= 1.6 F2,18= 4.5 # F2,18= 0.5 
        vehicle nd nd nd 356 ± 16 262 ± 10 323 ± 12 
        F2MPA 1    547 ± 14* 484 ± 21* 405 ± 6* 
        F2MPA 4    633 ± 9* 243 ± 6 478 ± 13* 
ANOVA    F2,15= 108 # F2,15= 340 # F2,15= 18 # 
       
HIPPOCAMPUS       
        vehicle nd nd nd 390 ± 67 161 ± 34 409 ± 57 
        Clor. 1    418 ± 95 241 ± 51 237 ± 57 * 
        Clor. 4    260 ± 55 284 ± 96 180 ± 35 * 
ANOVA    F2,18= 1.2 F2,17= 0.9 F2,18= 5.6 # 
        Depr. 1    554 ± 74 139 ± 30 366 ± 52 
        Depr. 4    430 ± 109 140 ± 38 354 ± 75 
ANOVA    F2,18= 1.3 F2,17= 0.2 F2,18= 0.8 
        vehicle nd nd nd 508 ± 43 177 ± 9 420 ± 79 
        F2MPA 1    512 ± 34 239 ± 24 417 ± 26 
        F2MPA 4    505 ± 51 266 ± 65 306 ± 61 
ANOVA    F2,15= 0.01 F2,15= 1.3 F2,15= 1.3 
 
Results are expressed in picograms/mg of tissue in the striatum, the cortex and the hippocampus. Clor. and 
Depr. correspond to clorgyline and deprenyl, respectively. 1 and 4 indicate the dose in mg/kg. nd, not 
detected; *p<0.05, (PLSD test). The results of the one-way ANOVA has been given below each 
experimental group together with the indication of its significance (#p<0.05). The vehicle group (n=7) was 
identical for clorgyline (n= 7 for both doses) and deprenyl (n=7 for both doses) experiments. The F2MPA 
experiment at 1 (n=6) or 4 (n=5) mg/kg was performed separately with its own vehicle group (n= 5). 
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Table	2.	Kinetic	parameters	for	inactivation	of	MAO	at	30°C	by	propargyl	compounds.	
Enzyme Parameter FMPA Clorgyline Deprenyl 
IC50 (30 min)     
hMAO A IC50 232 ± 15 µM 0.23 ± 0.05 nM 17.0 ± 0.4 µM 
hMAO B IC50 8.9 ± 1.2 µM 10.6 ± 0.95 µM  12.6 ± 1.1 nM 
Rat MAOa     
      MAO A IC50 121 ± 55 µM 1.81 ± 0.60 nM 17.6 ± 6.7 µM 
      MAO B IC50 4.15 ± 0.42 µM 4.2 ± 1.2 µM 7.8 ± 1.1 nM 
 Inactivation     
hMAO A kinact (min-1) 0.087 ± 0.010 0.157 ± 0.018* 0.252 ± 0.081 
 KI (µM) 187 ± 37 0.031 ± 0.009* 193 ± 55 
 kinact/KI 0.0005 5.06 0.0013 
     
hMAO B kinact (min-1) 0.61 ± 0.09 0.020 ± 0.001 1.06 ± 0.25  
 KI (µM) 135 ± 23 1.8 ± 0.6 0.18 ± 0.05 
 kinact/KI 0.0045 0.10 5.89 
     
Rat MAO Bb kinact (min-1) 0.53 ± 0.03   
 KI (µM) 65 ± 7    
 kinact/KI 0.0082   
	
aAll three inhibitors gave biphasic dose-response curves  for rat MAO inactivation. The smaller fraction 
(34%) is identified as MAO A by the high affinity clorgyline inhibition; the larger fraction (66%) 
inhibited at high affinity by deprenyl is identified as MAO B.  
bRat liver homogenate was pre-treated with clorgyline to block MAO A.   
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Table 3. Data collection and refinement statistics for the human MAO B-F2MPA complex 
PDB code XXXX 
Space group C222 
Unit cell axes (Å) a = 131.8, b = 223.2, c = 86.5 
Resolution (Å) 2.4 
Rsyma,b (%) 16.5 (75.1) 
CC1/2 (%) 99.0 (78.1) 
Completenessb (%) 98.4 (95.4) 
Unique reflections 48,068 
Redundancy 7.7 (6.7) 
I/σb 9.9 (4.0) 
N° of atoms 
protein/FAD/ligand/water  
 
7915/2x53/2x11/223 
Average B value for 
ligand atoms (Å2) 
 
48.3 
Rcrystb,c (%) 17.0 (23.2) 
Rfreeb,c (%) 23.7 (31.3) 
Rms bond length (Å) 0.016 
Rms bond angles (°) 1.76 
 
a Rsym=∑|Ii-<I>|/∑Ii, where Ii is the intensity of ith observation and <I> is the mean intensity of the 
reflection.  
b Values in parentheses are for reflections in the highest resolution shell. 
c Rcryst=∑|Fobs-Fcalc|/∑|Fobs| where Fobs and Fcalc are the observed and calculated structure factor amplitudes, 
respectively. Rcryst and Rfree were calculated using the working and test sets, respectively. 
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